This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tigatuzumab

Daiichi Sankyo Co., Ltd.

Drug Names(s): R-161460, TRA-8, CS-1008, CS1008

Description: CS-1008 is a humanized anti-DR5 antibody. DR5 mimics the action of TRAIL and activates the apoptosis pathway. DR5 is expressed in many tumor cell lines.

Deal Structure: The compound was discovered by Sankyo and the University of Alabama and is being developed by Sankyo.


Tigatuzumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug